Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s00705-021-04956-9 http://scihub22266oqcxt.onion/10.1007/s00705-021-04956-9 33492523!7829645!33492523     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33492523&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Arch+Virol 2021 ; 166 (3): 949-954 Nephropedia Template TP {{tp|p=33492523|t=2021. Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study |pdf=|usr=}}{{33492523}} gab.com Text Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study JO: Arch Virol http://www.kidney.de/pget.php?&tw=1&pmid=33492523 #FOAvip No specific antiviral drugs have been approved for the treatment of COVID-19. This study aimed to evaluate the efficacy of favipiravir in treatment of COVID-19. This was a multicenter randomized controlled study including 96 patients with COVID- 19 who were randomly assigned into a chloroquine (CQ) group and a favipiravir group. None of the patients in the favipiravir group needed mechanical ventilation (p = 0.129). One patient (2.3%) in the favipiravir group and two patients (4.2%) in the CQ group died (p = 1.00). Favipiravir is a promising drug for COVID-19 that decreases the hospital stay and the need for mechanical ventilation.ClinicalTrials.gov Identifier NCT04351295. Twit Text FOAVip Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study ????Arch Virol http://www.kidney.de/pget.php?&tw=1&pmid=33492523 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33492523 #FOAvip English Wikipedia <ref>{{Cite pmid|33492523}}</ref> Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study #MMPMID33492523 Dabbous HM; Abd-Elsalam S; El-Sayed MH; Sherief AF; Ebeid FFS; El Ghafar MSA; Soliman S; Elbahnasawy M; Badawi R; Tageldin MA Arch Virol 2021[Mar]; 166 (3): 949-954 PMID33492523show ga No specific antiviral drugs have been approved for the treatment of COVID-19. This study aimed to evaluate the efficacy of favipiravir in treatment of COVID-19. This was a multicenter randomized controlled study including 96 patients with COVID- 19 who were randomly assigned into a chloroquine (CQ) group and a favipiravir group. None of the patients in the favipiravir group needed mechanical ventilation (p = 0.129). One patient (2.3%) in the favipiravir group and two patients (4.2%) in the CQ group died (p = 1.00). Favipiravir is a promising drug for COVID-19 that decreases the hospital stay and the need for mechanical ventilation.ClinicalTrials.gov Identifier NCT04351295. |*COVID-19 Drug Treatment[MESH] |Adult[MESH] |Amides/*therapeutic use[MESH] |Antiviral Agents/*therapeutic use[MESH] |Chloroquine/therapeutic use[MESH] |Female[MESH] |Humans[MESH] |Length of Stay[MESH] |Male[MESH] |Pyrazines/*therapeutic use[MESH] |Respiration, Artificial/statistics & numerical data[MESH] |SARS-CoV-2/*drug effects[MESH]Efficacy of favipiravir in COVID-19 treatment: a multi-center randomiz(epmc).pdf DeepDyve Pubget Overpricing